[Clinical and pharmacokinetic study of ceftriaxone in severe infections in adults in intensive care].
Twenty patients with severe nosocomial bacterial infections hospitalized in an intensive care unit were treated by ceftriaxone alone, in a single daily IV injection of 2 g. Clinical and bacteriological results show that ceftriaxone has good activity against enterobacteria. The four patients (20%) who failed to respond had superinfection by Pseudomonas aeruginosa, a finding that suggests that ceftriaxone should be used in combination with another antibiotic for the treatment of nosocomial infections. Pharmacokinetic results in our patients show that with the dosage used peak and trough serum levels are greater than the MICs of susceptible pathogens.
D000328:Adult; D000368:Aged; D001996:Bronchopneumonia / Q000188:drug therapy* / Q000209:etiology; D002443:Ceftriaxone / Q000097:blood / Q000627:therapeutic use*; D003422:Critical Care; D003428:Cross Infection / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy
D002443:Ceftriaxone
Etude clinique et pharmacocinétique de la ceftriaxone dans les infections sévères de l'adulte en réanimation.